

On 7 January 2010, the Commission decided to initiate antitrust proceedings in case COMP/39226 – Lundbeck within the meaning of Article 11(6) of Council Regulation No 1/2003 and Article 2(1) of Commission Regulation No 773/2004.

The proceedings were opened against the pharmaceutical undertaking Lundbeck with a view to adopting a decision in application of Chapter III of Council Regulation No 1/2003. The facts, to be investigated further, concern unilateral practices and/or agreements with the object or effect of preventing or delaying entry of generic citalopram into the markets of citalopram in the European Economic Area (EEA). Citalopram is an anti-depressant drug. These suspected practices and/or agreements constitute possible infringements of Article 101 and/or Article 102 of the Treaty on the Functioning of the European Union and Article 53 and/or Article 54 of the EEA Agreement.

The initiation of proceedings does not mean that the Commission has proof of an infringement, only that the Commission will deal with the case as a matter of priority.